JPRN-jRCT2061230061招募中1 期
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan
Hayakawa Jin0 个研究点目标入组 85 人开始时间: 2023年9月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have T-cell Lymphoma with relapsed or refractory disease, as assessed by the investigator
- •- Phase 1 participants must not be responsive, intolerant, or ineligible to standard therapies that may prolong life or provide symptomatic relief, or
- •for whom no standard therapeutic option is available in the clinical practice guidelines in the opinion of the investigator.
- •- Phase 2 participants must have been treated by at least 1 prior line of systemic therapy.
- •- Have an Eastern Cooperative Oncology Group performance status of 0, 1 or 2.
排除标准
- •- Have any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participants from participating in
- •- Have any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, which places the participants at unacceptable risk if he/she were to participate in the study.
- •- Have a life expectancy <=3 months.
研究者
相似试验
进行中（未招募）
1 期
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069)EUCTR2021-000493-29-NLBristol-Myers Squibb International Corporation99
进行中（未招募）
1 期
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113EUCTR2011-005718-12-ESARIAD Pharmaceuticals, Inc.137
进行中（未招募）
1 期
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas(RELATIVITY-069)CTIS2023-503715-14-00Bristol Myers Squibb International Corporation99
尚未招募
2 期
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin LymphomaHodgkin Lymphoma and Non-Hodgkin Lymphoma10025319NL-OMON53587Bristol-Myers Squibb2
进行中（未招募）
1 期
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069)Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025322Term: Lymphomas non-Hodgkin's unspecified histologySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-000493-29-ESBristol-Myers Squibb International Corporation99